ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Effects of Vornorexant, a Dual Orexin Receptor Antagonist, on Bladder Function in Rats and Nocturnal Voiding Frequency in Patients With Insomnia.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comment on "Effects of Vornorexant, a Dual Orexin Receptor Antagonist, on Bladder Function in Rats and Nocturnal Voiding Frequency in Patients With Insomnia".International journal of urology : official journal of the Japanese Urological Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNocturia has been reported to exacerbate sleep disturbances, such as insomnia and poor sleep quality, resulting in increased risks of falls, fractures, and mortality. These consequences significantly impact the physical health and overall prognosis of patients. Dual orexin receptor antagonists, prescribed for the treatment of insomnia, have been shown to reduce nocturnal voiding frequency. However, the mechanisms underlying this effect are not yet fully elucidated.
methodsIntercontraction intervals and micturition pressure were measured using cystometry following intraduodenal administration of vornorexant to anesthetized rats. Subsequently, urine production was assessed following oral administration of vornorexant in a water-loaded rat model. To evaluate the effect of vornorexant on nocturnal voiding frequency in patients with comorbid insomnia and mild nocturia, a post hoc analysis was conducted using data from a prior clinical study in Japanese patients. Participants were stratified by baseline voiding frequency (0 vs. ≥ 1 voids/night), and nocturnal voiding frequency was summarized.
resultsIn the anesthetized rats, vornorexant significantly prolonged intercontraction intervals without affecting micturition pressure. In the water-loaded rats, vornorexant did not significantly affect urine volume. In this exploratory post hoc analysis, bedtime vornorexant significantly but modestly reduced nocturnal voiding compared with placebo in patients with ≥ 1 voids/night at baseline.
conclusionsThese findings suggest that vornorexant may improve nocturia in patients with comorbid insomnia and mild nocturia, potentially through the modulation of micturition control pathways. Future clinical studies could explore the potential of improving nocturia through modulation of the micturition control pathway, which may open new possibilities for targeted therapeutic interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.